CoChat

Best Practices in the Management of Overweight and Obesity

Tchang, Beverly G., Saunders, Katherine H., Igel, Leon I. · 2021 · Medical Clinics of North America
Cited by 91

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

Obesity is a chronic disease caused by dysregulated energy homeostasis pathways that encourage the accumulation of adiposity, which in turn results in the development or exacerbation of weight-related comorbidities. Treatment of obesity relies on a foundation of lifestyle modification; weight loss pharmacotherapy, bariatric surgery and devices are additional tools to help patients achieve their health goals. Appropriate management of patients with obesity provides multiple metabolic benefits beyond weight loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mcna.2020.08.018

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 21

  1. National Heart, Lung, and Blood Institute Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Obesity in Adults (US). Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda (MD): National Heart, Lung, and Blood Institute. 1998;98(4083):1–262.
  2. Bays, 2008, Is adiposopathy (sick fat) an endocrine disease?, Int J Clin Pract, 62, 1474, 10.1111/j.1742-1241.2008.01848.x · DOI · Paper page
  3. World Health Organization, 2004, Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies, Lancet, 363, 157, 10.1016/S0140-6736(03)15268-3 · DOI · Paper page
  4. Gabel, 2018, Effects of 8-hour time restricted feeding on body weight and metabolic disease risk factors in obese adults: a pilot study, Nutr Healthy Aging, 4, 345, 10.3233/NHA-170036 · DOI · Paper page
  5. Westman, 2007, Low-carbohydrate nutrition and metabolism, Am J Clin Nutr, 86, 276, 10.1093/ajcn/86.2.276 · DOI · Paper page
  6. Donnelly, 2003, Effects of a 16-month randomized controlled exercise trial on body weight and composition in young, overweight men and women: the Midwest Exercise Trial, Arch Intern Med, 163, 1343, 10.1001/archinte.163.11.1343 · DOI · Paper page
  7. Aristizabal, 2015, Effect of resistance training on resting metabolic rate and its estimation by a dual-energy X-ray absorptiometry metabolic map, Eur J Clin Nutr, 69, 831, 10.1038/ejcn.2014.216 · DOI
  8. Klem, 1997, A descriptive study of individuals successful at long-term maintenance of substantial weight loss, Am J Clin Nutr, 66, 239, 10.1093/ajcn/66.2.239 · DOI · Paper page
  9. Igel, 2017, Practical use of pharmacotherapy for obesity, Gastroenterology, 152, 1765, 10.1053/j.gastro.2016.12.049 · DOI
  10. Rothman, 2001, Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin, Synapse, 39, 32, 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3 · DOI · Paper page
  11. Garvey, 2012, Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study, Am J Clin Nutr, 95, 297, 10.3945/ajcn.111.024927 · DOI · Paper page
  12. Greenway, 2009, Rational design of a combination medication for the treatment of obesity, Obesity (Silver Spring), 17, 30, 10.1038/oby.2008.461 · DOI · Paper page
  13. Greenway, 2010, Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 376, 595, 10.1016/S0140-6736(10)60888-4 · DOI · Paper page
  14. Colquitt, 2014, Surgery for weight loss in adults, Cochrane Database Syst Rev
  15. Barenbaum, 2018, Obesity: when to consider surgery, J Fam Pract, 67, 614
  16. Saunders, 2018, Devices and endoscopic bariatric therapies for obesity, Curr Obes Rep, 7, 162, 10.1007/s13679-018-0307-x · DOI
  17. Grundy, 2005, Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement, Circulation, 112, 2735, 10.1161/CIRCULATIONAHA.105.169404 · DOI · Paper page
  18. 2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 · DOI · Paper page
  19. 2020, 2. Classification and diagnosis of diabetes, Diabetes Care, 43, S14
  20. Sullivan, 2016, The Obalon Swallowable 6-Month Balloon System is More Effective Than Moderate Intensity Lifestyle Therapy Alone: Results From a 6- Month Randomized Sham Controlled Trial, Gastroenterology, 150, S1267, 10.1016/S0016-5085(16)34281-0 · doi:10.1016/s0016-5085(16)34281-0
  21. Thompson, 2016, The AspireAssist is an effective tool in the treatment of class II and class III obesity: results of a one-year clinical trial, Gastroenterology, 150, S86, 10.1016/S0016-5085(16)30406-1 · DOI

Cited by

See all 91

Metadata

Authors
Tchang, B. G., Saunders, K. H., & Igel, L. I.
Venue
Medical Clinics of North America
Publisher
Elsevier BV
Published
2021-01
Volume
105
Issue
1
Pages
149-174
ISSN
0025-7125 (ISSN-L)
OpenAlex
W3098936336
Cited by
91
References
46
FWCI
6.94
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
Novo Nordisk

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.